AFINUM acquires majority stake in evitria AG
AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG acquired a majority stake in the Schlieren (Switzerland) based biotech company evitria AG from its founder. evitria AG is one of the leading providers of custom antibodies for research purposes.
VISCHER advised AFINUM on all legal aspects of this transaction. The VISCHER team was led by Jürg Luginbühl (Partner, Corporate/M&A) and included Sebastian P. Weber (Associate, Corporate/M&A), Stefan Kohler (Partner, Intellectual Property) and Adrian Dörig (Partner, Banking & Finance).